Additional biomarkers, such as p16/Ki-67 immunohistochemistry or DNA methylation assays, should also be considered to further enhance diagnostic precision and support the development of more personalized cervical cancer screening protocols. The gene discussed is MKI67; the disease is cervical cancer.